“ERNA’s Superior Stand in Biotech: Eterna Therapeutics Inc. NASDAQ Edge”
Unravel the financial health of bio-tech giants Eterna Therapeutics and PaxMedica through key metrics ROIC and WACC. Delve into how efficient capital management can make a company a worthy investment in a competitive landscape.ю Read more
Read More
“Bancorp Sustains Growth: Extends REBL Property Sale Contract”
Piper Sandler retains Overweight rating for The Bancorp (NASDAQ:TBBK) with a $64 price target, as the firm reveals extension of their REBL OREO property's sale agreement. The renewed investor confidence raises hopes for a modest stock spike, boosting Bancorp's long-term growth potential. Read more
Read More
“Core Health Focus Boosts Masimo’s Target to $194”
Analysts from Raymond James confidently revise their price target for Masimo (NASDAQ: MASI) to $194 from $170, highlighting the firm’s high-growth potential. Driven by a strategic shift back to its healthcare roots, paired with unique margin expansion initiatives and strong leadership, Masimo is expected to outperform the market and deliver sustainable growth. Read more
Read More